Inflammation and Heart Failure

Abstract

Heart failure (HF) is a common clinical syndrome caused by a variety of cardiac diseases. The morbidity and mortality have increased in the last decades. The pathophysiology of HF is exceedingly complex. It has developed from the simplistic model of pump failure to that of a multisystemic disorder that affects not only the cardiovascular system but also the musculoskeletal, neuroendocrine and immune systems. Apart from myocardial hypertrophy, the pathogenetic mechanisms of HF also include deregulation of the neurohormonal system, with disturbance of the balance between sympathetic and parasympathetic tone, and disruption of the rennin-angiotensin-aldosterone system. Activation of neurohormones and pro-inflammatory cytokines has been recognized in HF progression after an initial cardiac injury. It is becoming increasingly apparent that inflammatory mediators play a crucial role in the development of HF. The purpose of this chapter is to give a brief overview of the role of inflammation in heart failure from animal models to clinical disease.

COVID-19 Infection and Inflammation of the Heart

COVID-19, caused by the SARS-CoV-2 virus, has become a global health crisis with profound implications for the cardiovascular system. Among these, myocardial inflammation, or myocarditis, and heart failure (HF) represent significant complications. COVID-19-associated myocarditis can range from subclinical presentations to life-threatening scenarios, including severe heart failure and arrhythmias [80]. Furthermore, COVID-19 has been increasingly recognized as a trigger for HF in both patients with pre-existing cardiac conditions and those without prior cardiovascular disease. The mechanisms by which COVID-19 induces these complications are multifactorial, involving direct myocardial injury, systemic inflammation, and hemodynamic stress [81]. The hypercoagulable state and hypoxic injury associated with COVID-19 further contribute to myocardial damage and HF progression [82]. Understanding the mechanisms, clinical presentation, and management of these cardiac complications is crucial for improving patient outcomes.

Pathophysiology of Heart Failure and Cardiac Inflammation in COVID-19

• 1. Direct Myocardial Injury:

SARS-CoV-2 infects cardiac myocytes via the ACE2 receptor, leading to cell damage, apoptosis, and myocardial dysfunction. This direct injury reduces cardiac output and may precipitate acute HF, particularly in patients with underlying left ventricular dysfunction [83, 84].

• 2. Cytokine-Mediated Myocardial Depression:

The cytokine storm in severe COVID-19 cases leads to systemic inflammation, which negatively impacts myocardial contractility. Pro-inflammatory cytokines, such as TNF-α and IL-6, impair β-adrenergic signaling and promote myocardial fibrosis, further contributing to HF progression [84].

• 3. Volume Overload and Hemodynamic Stress:

COVID-19 often causes acute lung injury, leading to hypoxia and increased pulmonary pressures. This results in right ventricular strain and may precipitate right HF. Additionally, systemic inflammation and vascular injury increase vascular permeability, causing fluid overload that exacerbates HF [85].

• 4. Microvascular Thrombosis and Ischemic Injury:

The prothrombotic state induced by COVID-19 leads to microvascular obstruction, causing ischemic injury to the myocardium. This ischemia can reduce cardiac output and exacerbate HF in patients with coronary artery disease [86, 87].

• 5. Arrhythmias and Secondary HF:

COVID-19 can induce atrial and ventricular arrhythmias through direct myocardial involvement and electrolyte imbalances. Persistent arrhythmias, such as atrial fibrillation, increase the risk of HF by impairing ventricular filling and reducing cardiac efficiency [84].

Clinical Presentation of COVID-19-Related Myocarditis and HF

Patients with COVID-19-related myocarditis and heart failure may present with symptoms such as chest pain, dyspnea that may occur even at rest in severe cases, fatigue, palpitations, or syncope. Diagnostic findings typically include elevated cardiac biomarkers such as troponin and B-type natriuretic peptide, electrocardiographic abnormalities indicative of myocardial involvement, and characteristic changes on cardiac MRI, including myocardial edema and late gadolinium enhancement [88].

Management of Heart Failure in COVID-19

• 1. Supportive Care:

Oxygen supplementation and non-invasive ventilation are crucial for hypoxic patients. Fluid management must be carefully balanced to avoid exacerbating pulmonary congestion [89].

• 2. Pharmacological Interventions:

  • Standard HF Therapies: Continuation or initiation of ACE inhibitors, β-blockers, and diuretics in stable patients.

  • Anti-inflammatory Agents: Corticosteroids and IL-6 inhibitors (e.g., tocilizumab) can mitigate systemic inflammation and myocardial damage [90, 91].

  • COVID-19-specific therapies

  COVID-19-specific therapies with potential cardiovascular implications include antiviral, anti-inflammatory, and other supportive treatments that indirectly alleviate myocardial stress and heart failure (HF) exacerbation. Remdesivir, an antiviral agent, reduces SARS-CoV-2 replication and systemic inflammation, thereby alleviating myocardial stress associated with COVID-19 [92].

  • Anticoagulants, including low-molecular-weight heparin and direct oral anticoagulants, are crucial for preventing thromboembolic events and improving myocardial perfusion in COVID-19 patients

  • Finally, supportive measures such as high-flow nasal cannula and oxygen therapy are essential for reducing hypoxia-induced myocardial stress, contributing significantly to the management of HF in severe COVID-19 cases

• 3. Advanced HF Therapies:

Severe HF cases with cardiogenic shock may require inotropic support or mechanical circulatory assistance, such as ECMO or ventricular assist devices. Heart transplantation may be considered for select end-stage HF patients [93].

COVID-19 Vaccine and Inflammation of the Heart

The introduction of COVID-19 vaccines, particularly mRNA-based vaccines, has been pivotal in controlling the global pandemic by reducing severe illness, hospitalization, and death [94, 95]. However, rare cases of myocarditis and pericarditis, collectively referred to as inflammation of the heart, have been reported following COVID-19 vaccination, especially in younger males [96, 97]. While these cases are uncommon and generally mild, they warrant attention to ensure vaccine safety and public confidence [98].

Mechanisms of Vaccine-Associated Myocarditis

• 1. Immune-Mediated Response:

COVID-19 vaccines are designed to elicit a strong immune response against the SARS-CoV-2 spike protein. In rare cases, this robust immune activation may trigger unintended inflammation in the myocardium due to the release of pro-inflammatory cytokines and immune cell infiltration [99].

• 2. Molecular Mimicry:

The SARS-CoV-2 spike protein shares structural similarities with some myocardial proteins, potentially leading to cross-reactive immune responses. This phenomenon, known as molecular mimicry, can cause autoimmunity and localized myocardial inflammation [100, 101].

• 3. Adjuvant Effects:

Adjuvants, which enhance vaccine efficacy by stimulating the immune system, may inadvertently activate pathways that lead to myocarditis in predisposed individuals [102].

Clinical Features

Vaccine-associated myocarditis typically occurs within 1–5 days after the second dose of an mRNA vaccine, such as BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna), and is more commonly reported in males aged 16–29 years [103, 104]. Common symptoms include chest pain, palpitations, fatigue, and shortness of breath [88, 98, 105]. Diagnostic findings often reveal elevated cardiac biomarkers, such as troponin, electrocardiographic changes, and characteristic abnormalities on cardiac magnetic resonance imaging (MRI), including myocardial edema and late gadolinium enhancement [88, 106].

Epidemiology

The overall incidence of vaccine-associated myocarditis is very low, estimated at approximately 0.3–5 cases per 100,000 vaccine doses, with the highest rates observed in young males [107, 108]. Importantly, the risk of myocarditis is significantly higher following SARS-CoV-2 infection compared to vaccination, highlighting the protective benefits of vaccines against severe cardiovascular complications [85, 109].

Management

Management of vaccine-associated myocarditis is primarily supportive, as most cases are mild and self-limiting [110, 111]. Recommended treatments include:

• Rest and Observation: Patients are advised to avoid strenuous activity until symptoms resolve and cardiac biomarkers normalize [112].

• Pharmacological Therapy: Nonsteroidal anti-inflammatory drugs (NSAIDs) are typically sufficient for symptom relief. In cases of moderate inflammation, corticosteroids may be considered [113,114,115].

Follow-Up: Cardiac function is monitored with follow-up imaging to ensure complete recovery, and long-term sequelae are rare [115].

Risk-Benefit Consideration

Despite these rare adverse events, the benefits of COVID-19 vaccination far outweigh the risks, particularly given the significantly higher risk of myocarditis and other severe complications associated with COVID-19 infection. Ongoing surveillance and studies continue to enhance our understanding of vaccine safety and guide clinical management.